Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer

Thaer Khoury, Sadir Alrawi, Nithva Ramnath, Qiang Li, Melissa Grimm, Jennifer D Black, Dongfeng Tan

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Eukaryotic initiation factor 4E (eIF4E) and cyclin D1, two impor tant factors in cell-cycle progression, play key roles in the carcinogenesis of varied human cancers. However, eIF4E expression in non-small-cell lung cancer (NSCLC) and its association with cyclin D1 has received little investigation. One hundred forty-seven subjects with primary NSCLC, with long-term follow-up and essential clinicopathologic parameters (including age, sex, tumor grade, tumor stage, smoking history, performance status, weight loss, histology grade, and survival data) were evaluated based on expression of eIF4E and cyclin D1. Immunohistochemical analysis was per formed using monoclonal antibodies against eIF4E and cyclin D1. While 134 of 147 cases (91%) were positive for eIF4E, 82 of 136 cases (63%) were positive for cyclin D1. Western blot results were consistent with those illustrated by immunohistochemistry. While eIF4E(+) correlated with significantly shor ter patient survival (P = .03), cyclin D1(+) correlated with longer patient survival (P = .01). Assessment of coexpression of cyclin D1 and eIF4E shows greater value in determining the prognosis of NSCLC: patients with eIF4E(+)/cyclin D1(-) have poorer outcome, those with eIF4E(-)/cyclin D1(+) have a more favorable outcome, and those with eIF4E(+)/cyclin D1(+) have an intermediate outcome (P = .02). The negative effect on survival in patients with eIF4E(+) suggests its potential prognostic role in NSCLC. These results warrant fur ther investigation to explore the value of eIF4E in identifying patients with aggressive disease for adjuvant treatments.

Original languageEnglish (US)
Pages (from-to)58-66
Number of pages9
JournalClinical Lung Cancer
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Eukaryotic Initiation Factor-4E
Cyclin D1
Lung Neoplasms
Survival
Non-Small Cell Lung Carcinoma
Neoplasms

Keywords

  • Cytokeratin 7
  • Immunohistochemistry
  • Western blot
  • mRNA

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. / Khoury, Thaer; Alrawi, Sadir; Ramnath, Nithva; Li, Qiang; Grimm, Melissa; Black, Jennifer D; Tan, Dongfeng.

In: Clinical Lung Cancer, Vol. 10, No. 1, 01.01.2009, p. 58-66.

Research output: Contribution to journalArticle

Khoury, Thaer ; Alrawi, Sadir ; Ramnath, Nithva ; Li, Qiang ; Grimm, Melissa ; Black, Jennifer D ; Tan, Dongfeng. / Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. In: Clinical Lung Cancer. 2009 ; Vol. 10, No. 1. pp. 58-66.
@article{d2ea7486512f454da1419a0e058e69be,
title = "Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer",
abstract = "Eukaryotic initiation factor 4E (eIF4E) and cyclin D1, two impor tant factors in cell-cycle progression, play key roles in the carcinogenesis of varied human cancers. However, eIF4E expression in non-small-cell lung cancer (NSCLC) and its association with cyclin D1 has received little investigation. One hundred forty-seven subjects with primary NSCLC, with long-term follow-up and essential clinicopathologic parameters (including age, sex, tumor grade, tumor stage, smoking history, performance status, weight loss, histology grade, and survival data) were evaluated based on expression of eIF4E and cyclin D1. Immunohistochemical analysis was per formed using monoclonal antibodies against eIF4E and cyclin D1. While 134 of 147 cases (91{\%}) were positive for eIF4E, 82 of 136 cases (63{\%}) were positive for cyclin D1. Western blot results were consistent with those illustrated by immunohistochemistry. While eIF4E(+) correlated with significantly shor ter patient survival (P = .03), cyclin D1(+) correlated with longer patient survival (P = .01). Assessment of coexpression of cyclin D1 and eIF4E shows greater value in determining the prognosis of NSCLC: patients with eIF4E(+)/cyclin D1(-) have poorer outcome, those with eIF4E(-)/cyclin D1(+) have a more favorable outcome, and those with eIF4E(+)/cyclin D1(+) have an intermediate outcome (P = .02). The negative effect on survival in patients with eIF4E(+) suggests its potential prognostic role in NSCLC. These results warrant fur ther investigation to explore the value of eIF4E in identifying patients with aggressive disease for adjuvant treatments.",
keywords = "Cytokeratin 7, Immunohistochemistry, Western blot, mRNA",
author = "Thaer Khoury and Sadir Alrawi and Nithva Ramnath and Qiang Li and Melissa Grimm and Black, {Jennifer D} and Dongfeng Tan",
year = "2009",
month = "1",
day = "1",
doi = "10.3816/CLC.2009.n.009",
language = "English (US)",
volume = "10",
pages = "58--66",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer

AU - Khoury, Thaer

AU - Alrawi, Sadir

AU - Ramnath, Nithva

AU - Li, Qiang

AU - Grimm, Melissa

AU - Black, Jennifer D

AU - Tan, Dongfeng

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Eukaryotic initiation factor 4E (eIF4E) and cyclin D1, two impor tant factors in cell-cycle progression, play key roles in the carcinogenesis of varied human cancers. However, eIF4E expression in non-small-cell lung cancer (NSCLC) and its association with cyclin D1 has received little investigation. One hundred forty-seven subjects with primary NSCLC, with long-term follow-up and essential clinicopathologic parameters (including age, sex, tumor grade, tumor stage, smoking history, performance status, weight loss, histology grade, and survival data) were evaluated based on expression of eIF4E and cyclin D1. Immunohistochemical analysis was per formed using monoclonal antibodies against eIF4E and cyclin D1. While 134 of 147 cases (91%) were positive for eIF4E, 82 of 136 cases (63%) were positive for cyclin D1. Western blot results were consistent with those illustrated by immunohistochemistry. While eIF4E(+) correlated with significantly shor ter patient survival (P = .03), cyclin D1(+) correlated with longer patient survival (P = .01). Assessment of coexpression of cyclin D1 and eIF4E shows greater value in determining the prognosis of NSCLC: patients with eIF4E(+)/cyclin D1(-) have poorer outcome, those with eIF4E(-)/cyclin D1(+) have a more favorable outcome, and those with eIF4E(+)/cyclin D1(+) have an intermediate outcome (P = .02). The negative effect on survival in patients with eIF4E(+) suggests its potential prognostic role in NSCLC. These results warrant fur ther investigation to explore the value of eIF4E in identifying patients with aggressive disease for adjuvant treatments.

AB - Eukaryotic initiation factor 4E (eIF4E) and cyclin D1, two impor tant factors in cell-cycle progression, play key roles in the carcinogenesis of varied human cancers. However, eIF4E expression in non-small-cell lung cancer (NSCLC) and its association with cyclin D1 has received little investigation. One hundred forty-seven subjects with primary NSCLC, with long-term follow-up and essential clinicopathologic parameters (including age, sex, tumor grade, tumor stage, smoking history, performance status, weight loss, histology grade, and survival data) were evaluated based on expression of eIF4E and cyclin D1. Immunohistochemical analysis was per formed using monoclonal antibodies against eIF4E and cyclin D1. While 134 of 147 cases (91%) were positive for eIF4E, 82 of 136 cases (63%) were positive for cyclin D1. Western blot results were consistent with those illustrated by immunohistochemistry. While eIF4E(+) correlated with significantly shor ter patient survival (P = .03), cyclin D1(+) correlated with longer patient survival (P = .01). Assessment of coexpression of cyclin D1 and eIF4E shows greater value in determining the prognosis of NSCLC: patients with eIF4E(+)/cyclin D1(-) have poorer outcome, those with eIF4E(-)/cyclin D1(+) have a more favorable outcome, and those with eIF4E(+)/cyclin D1(+) have an intermediate outcome (P = .02). The negative effect on survival in patients with eIF4E(+) suggests its potential prognostic role in NSCLC. These results warrant fur ther investigation to explore the value of eIF4E in identifying patients with aggressive disease for adjuvant treatments.

KW - Cytokeratin 7

KW - Immunohistochemistry

KW - Western blot

KW - mRNA

UR - http://www.scopus.com/inward/record.url?scp=62549083454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549083454&partnerID=8YFLogxK

U2 - 10.3816/CLC.2009.n.009

DO - 10.3816/CLC.2009.n.009

M3 - Article

VL - 10

SP - 58

EP - 66

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -